State Street Corp Buys 150,323 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

State Street Corp increased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 6.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,433,963 shares of the biopharmaceutical company’s stock after buying an additional 150,323 shares during the period. State Street Corp’s holdings in Revance Therapeutics were worth $12,632,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in Revance Therapeutics by 22.5% during the second quarter. Bank of New York Mellon Corp now owns 373,015 shares of the biopharmaceutical company’s stock worth $959,000 after purchasing an additional 68,451 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Revance Therapeutics by 47.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,961 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 10,638 shares during the period. Rhumbline Advisers lifted its holdings in Revance Therapeutics by 11.6% during the 2nd quarter. Rhumbline Advisers now owns 136,347 shares of the biopharmaceutical company’s stock valued at $350,000 after purchasing an additional 14,191 shares during the last quarter. CM Management LLC increased its holdings in shares of Revance Therapeutics by 60.0% in the second quarter. CM Management LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $1,028,000 after purchasing an additional 150,000 shares during the last quarter. Finally, Arizona State Retirement System raised its position in shares of Revance Therapeutics by 27.6% in the second quarter. Arizona State Retirement System now owns 27,716 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,996 shares during the period. 97.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on RVNC shares. Mizuho decreased their price target on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research note on Tuesday, December 10th. StockNews.com assumed coverage on Revance Therapeutics in a report on Friday, December 20th. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. Finally, Barclays lowered their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday. Nine equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Trading Up 0.3 %

NASDAQ RVNC opened at $3.08 on Thursday. Revance Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $9.74. The firm has a market capitalization of $321.52 million, a price-to-earnings ratio of -1.60 and a beta of 0.82. The firm’s 50 day simple moving average is $4.26 and its 200 day simple moving average is $4.50.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to the consensus estimate of $67.73 million. On average, equities research analysts forecast that Revance Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.